FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used to predict the risk of adverse outcomes in patients with stable ischemic heart disease within 1 year after a percutaneous coronary intervention with stenting. Method comprises determining initial levels of interleukin-17 (IL-17) and interleukin-6 (IL-6) in blood serum by enzyme-linked immunosorbent assay, and then calculating risk of unfavorable outcomes by formula
,
where e is base of natural logarithm, e = 2.72, Z is calculated by formula Z = (-5.1 + (0.08) * x + (0.066) * y), x is content of IL-17 in blood serum in pg/ml, y – content of IL-6 in blood serum in pg/ml, and risk of developing adverse cardiovascular events is considered to be high while value K ≥ 0.13, and low – while K < 0.13.
EFFECT: use of the method enables higher accuracy of assessing the risk of unfavorable outcomes for 1 year after the percutaneous coronary intervention with stenting in the patients with stable coronary artery disease, which in turn will allow optimizing the therapeutic approach in these patients.
1 cl, 1 dwg, 3 tbl, 2 ex
